Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors
Phase of Trial: Phase I/II
Latest Information Update: 06 Oct 2018
At a glance
- Drugs BMS-986277 (Primary) ; Nivolumab (Primary)
- Indications Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb
- 18 Jul 2018 Planned number of patients changed from 146 to 200.
- 02 Apr 2018 Planned End Date changed from 28 Jun 2021 to 29 Dec 2022.
- 02 Apr 2018 Planned primary completion date changed from 27 Jun 2021 to 28 Sep 2022.